Clinical significance of serum CYFRA 21-1 in gastric cancer

British Journal of Cancer

Volumn 73, Issue 12, 1996, Pages 1529-1532

  Nakata, B ^a   Chung, Y S ^a   Kato, Y ^a   Ogawa, M ^a   Ogawa, Y ^a   Inui, A ^a   Maeda, K ^a   Sawada, T ^a   Sowa, M ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinicopathological factor; CYFRA 21 1; Gastric cancer; Prognosis

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ANTIBODY TITER; ARTICLE; CANCER INVASION; CANCER STAGING; ENZYME IMMUNOASSAY; HUMAN; LIVER METASTASIS; PERITONEUM METASTASIS; PRIORITY JOURNAL; STOMACH CANCER;

EID: 0030037680     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.288     Document Type: Article

References (19)

1. BODENMÜLLER H, BANAUCH D, OFENLOCH-HÄHNLE B, JAWOREK D AND DESSAUER A. (1992). Technical evaluation of a new automated tumor marker assay: The enzymun-test Cyfra 21.1, In Tumor associated Antigens, Oncogenes, Receptors, Cytokines in Tumor Diagnosis and Therapy at the Beginning of the Nineties. Cancer of the Breast, State and Trends in Diagnosis and Therapy, Klapdor R (ed.) pp. 137-138. Zuckschwerdt: Munich.
2. CYK and CYFRA21-1 react differently with the keratins 8, 18 and 19. Int. J. Biol. Markers, 9, 70-74.
3. BODENMÜLLER H, OFENLOCH-HÄHNLE B, LANE EB, DKSSUAR A, BOTTGER V AND DONIE F. (1994b). Lung cancer-associated keratin 19 fragments: development and biochemical characterization of the new serum assay Enzymun-Test CYFRA 21-1. Int. J. Biol. Markers, 9, 75-81.
4. BONFRER JM, GAARENSTROOM KN, KENTER GG, KORSE CM, HART AA, GALLEE MP, HELMERHORST TJ AND KENEMANS P. (1994). Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer. Gynecol. Oncol., 55, 371-375.
5. BROERS JL, RAMAEKERS FC, ROT MK, OOSTENDORF T, HUYSMANS A, VAN MUIJEN GN, WAGENAAR SS AND VOOIJIS GP. (1988). Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res., 48, 3221-3229.
6. DEBUS E, MOLL R, FRANKE WW, WEBER K AND OSBORN M. (1984). Immunohistochemical distinction of human carcinomas by cytokeratin typing with monoclonal antibodies. Am. J. Pathol., 114, 121-130.
7. DOWECK I, BARAK M, GREENBERG E, URI N, KELLNER J, LURIE M AND GRUENER N. (1995). Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Arch. Otularyngol. Head Neck Surg., 121, 177-181.
8. FERDEGHINI M, GADDUCCI A, ANNICCHIARICO C, PRONTERA C, MALAGNINO G, CASTELLANI C, FACCHINI V AND BIANCHI R. (1993). Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix. Anticancer Res., 13, 1841-1844.
9. JAPANESE RESEARCH SOCIETY FOR GASTRIC CANCER. (1995). Japanese Classification of Gastric Carcinoma. First English edition. Kanchara: Tokyo.
10. MOLINA R, AGUSTI C, FILELLA X, JO J, JOSEPH J, GIMÉNEZ N AND BALLESTA AM. (1994). Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. Tumor Biol., 15, 318-325.
11. MOLL R, FRANKE WW, SCHILLER DL, GEIBER B AND KREPLER R. (1982). The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell, 31, 11-24.
12. PUJOL J-L, GRENIER J, DAURÈS J-P, DAVER A, PUJOL H AND MICHEL F-B. (1993). Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res., 53, 61-66.
13. STEINERT PM AND ROOP DR. (1988). Molecular and cellular biology of intermediate filaments. Ann. Rev. Biochem., 57, 593-625.
14. STIEBER P, BODENMÜLLER H, BANAUCH D, HASHOLZNER U, DESSAUER A, OFENLOCH-HÄHNLE B, JAWOREK D AND FATEH-MOGHADAM A. (1993a). Cytokeratin 19 fragments: a new marker for non-small-cell lung cancer. Clin. Biochem., 26, 301-304.
15. STIEBER P, HASHOLZNER U, BODENMÜLLER H, NAGEL D, SUNDER-PLASSMAN L, DIENEMANN H, MEIER W AND FATEH-MOGHADAM A. (1993b). CYFRA 21-1. A new marker in lung cancer. Cancer, 72, 707-713.
16. SUGAMA Y, KITAMURA S, KAWAI T, OHKUBO A, HASEGAWA S, KURIYAMA T, KATO H, FUKUOKA M AND OHKAWA J. (1994). Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn. J. Cancer Res., 85, 1178-1184.
17. SUNDSTRÖM BE, NATRATH WBJ AND STIGBRAND T. (1989). Diversity in immunoreactivity of tumor derived cytokeratin monoclonal antibodies. Histochem. Cytochem., 37, 1848-1854.
18. TAKADA M, MASUDA N, MATSUURA E, KUSUNOKI Y, MATUI K, NAKAGAWA K, YANA T, TUYUGUCHI I, OOHATA I AND FUKUOKA M. (1995). Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. Br. J. Cancer, 71, 160-165.
19. VAN DER GAAST A, SCHOENMAKERS CHH, KOK TC, BLIJENBERG BG, CORNILLIE F AND SPLINTER TAW. (1994). Evaluation of a new tumor marker in patients with non-small-cell lung cancer: Cyfra 21-1. Br. J. Cancer, 69, 525-528.